ReviewCancer biology & therapy2018
Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration.
Review in Cancer biology & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Establishment and genomic validation of novel patient-derived xenograft models for drug discovery in gastrointestinal stromal tumor.BMC cancer · 2026Article
- Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges.Frontiers in pharmacology · 2026Review
- Prediction of the Prognosis and Treatment Responses Based on the Characteristics of Disulfidptosis-Related Genes in Patients with Cervical Squamous Cell Carcinoma and Endocervical AdenocarcinomaEndocrine, metabolic & immune disorders drug targets · 2026Article
- Topical vaginal drug therapy in cervical cancer management: a review of clinical trials and preclinical evidence.Medical oncology (Northwood, London, England) · 2025Review
- Bioprinting for drug screening: A path toward reducing animal testing or redefining preclinical research?Bioactive materials · 2025Review
- Review
- Construction of an Extracellular Matrix-Related Risk Model to Analyze the Correlation Between Glioblastoma and Tumor Immunity.BioMed research international · 2025Article
- Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy.Cancer medicine · 2024Article
- Construction and analysis of a reliable five-gene prognostic signature for colon adenocarcinoma associated with the wild-type allelic state of theTranslational cancer research · 2024Article
- Optimizing culturing conditions in patient derived 3D primary slice cultures of head and neck cancer.Frontiers in oncology · 2023Article
- Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool.International journal of molecular sciences · 2022Article
- Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET.Biomedicines · 2022Review
- Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer.Frontiers in oncology · 2022Review
- Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Tissues and Tumor Microenvironment (TME) in 3D: Models to Shed Light on Immunosuppression in Cancer.Cells · 2021Review
- Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.Journal for immunotherapy of cancer · 2021Article
- A New Antitumor Direction: Tumor-Specific Endothelial Cells.Frontiers in oncology · 2021Review
- CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence.Cancer management and research · 2021Article
- The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment.Frontiers in cell and developmental biology · 2021Review
- Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
In cancer immunotherapy, cytotoxic T or NK cells need to engage cancer cells to initiate the killing. However, in clinical studies and in mouse models, some solid tumors are found with no lymphocytes. It is likely that these tumors will be resistant to all sorts of immunotherapies. Thus, restoring lymphocytic infiltration will be vital to the success of immunotherapies on solid tumors. In order to understand the complex interaction between cancer cells and stromal cells, we propose to establish animal models for studying the tumor microenvironment and to develop and test therapies to restore lymphocytic infiltration of tumors Without lymphocytes infiltrating tumors, all immunotherapies on solid tumors become ineffective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.